Accepted Articles                   Back to the articles list | Back to browse issues page

XML Print


1- Associate Professor, Pediatric Infectious Diseases Research Center, Mazandaran University of Medical Sciences, Sari, Iran , rezai@mazums.ac.ir
2- Pediatric Infectious Diseases Research Centre, Mazandaran University of Medical Sciences, Sari, Iran
3- Department of Clinical Pharmacy, Faculty of Pharmacy, Cardiovascular Research Center, Mazandaran, Sari, Iran
4- Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran
5- Department of Pediatrics, Division of Pulmonary, Penn State College of Medicine, Hershey, PA, USA
Abstract:   (74 Views)

Context: The use of ciprofloxacin is contra-indicated in children due to the safety concerns. Animal studies have shown that ciprofloxacin can be associated with arthropathy (joint toxicity) in juvenile animals; however, this potential side effect has not been proven in paediatrics. Many clinicians still prescribe ciprofloxacin when no suitable alternative is available for. In many developing countries, the access to the newer generation of antibiotics are either limited or expensive, therefore ciprofloxacin is an available and cost-effective alternative option that can save lives when needed.
Objectives: The aim of this study was to systemically review the published studies about the safety profile of using ciprofloxacin in pediatrics.
Data sources, study selection and data extraction: All relevant studies published from 1990 to 2018 in Cochrane library, Trip database, Science Direct, PubMed and Google scholar have been collected. We have only included clinical trial studies, which included ciprofloxacin, children under 18 years old, and arthropathy. Data were analyzed by Comprehensive Meta-Analysis software version 2 (CMA.2) and we used the random fixed-effect method base on heterogeneity result. Heterogeneity was checked by I2 index and Tau squared. Publication bias was evaluated by the Begg test.
Results: Researches have not shown an increased risk of arthropathy when ciprofloxacin is used in pediatrics on a short-term basis in comparison to placebo or other antibiotics.
Conclusion: It can be concluded that ciprofloxacin is potentially a safe alternative to be used in children under the age of 18 years old when no better alternative available.
Keywords: Paediatrics, Ciprofloxacin, Safety profile, Arthropathy, Fluoroquinolones

 
 
Full-Text [PDF 1029 kb]   (47 Downloads)    
Type of Study: Meta-analysis Review | Subject: Pediatric infection disease
Received: 2018/08/28 | Accepted: 2018/10/17

Add your comments about this article : Your username or Email:
CAPTCHA code

Send email to the article author


© 2018 All Rights Reserved | Journal of Pediatrics Review

Designed & Developed by : Yektaweb